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Although genetic and environmental factors are known to
contribute to AD and asthma, the mechanisms underlying the
atopic march remain poorly understood. Filaggrin loss-of-
function mutations are a major genetic predisposer for the
development of AD and progression to AD-associated asthma.
Objective: We sought to experimentally addresswhether filaggrin
mutations in mice lead to the development of spontaneous
eczematous inflammation and address the aberrant immunologic
milieu arising in a mouse model of filaggrin deficiency.
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482recruited AD case collections were analyzed to define associations
between filaggrin mutations and immunologic phenotypes.
Results: Filaggrin-deficient mice on a BALB/c background had
profound spontaneous AD-like inflammation with progression
to compromised pulmonary function with age, reflecting the
atopic march in patients with AD. Strikingly, skin inflammation
occurs independently of adaptive immunity and is associated
with cutaneous expansion of IL-5–producing type 2 innate
lymphoid cells. Furthermore, subjects with filaggrin mutations
have an increased frequency of type 2 innate lymphoid cells in
the skin in comparison with control subjects.
Conclusion: This study provides new insights into our
understanding of the atopic march, with innate immunity
initiating dermatitis and the adaptive immunity required for
subsequent development of compromised lung function. (J
Allergy Clin Immunol 2016;137:482-91.)
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There has been a profound increase in the incidence of atopic
disease morbidity in developed societies in recent decades.
Atopic individuals, who are characterized by increased serum
IgE levels, are predisposed to having allergies such as atopic
dermatitis (AD) and asthma. AD is heritable and characterized by
pruritic eczematous lesions, with approximately 20% of children
affected in the developed world.1 The cause of AD is multifacto-
rial, with interplay between genetic predisposition and environ-
mental factors initiating aberrant inflammation.2 The term
atopic march encapsulates the predisposition of patients with
AD in infancy to progress to secondary allergic disorders, such
as asthma.3 Although AD as the first manifestation of atopic
diathesis in early life is well established, how AD development
primes progression to secondary allergies is not known.
Loss-of-function mutations in the human filaggrin gene (FLG)
have been identified as the major genetic predisposing factor for
ADdevelopment,4-6 and in the context of the atopicmarch, patients
withADwithFLGmutations are predisposed to the development of
asthma.7,8 We previously identified a mutation in the murine filag-
grin gene (Flg) in the ‘‘flaky tail’’ double-mutant (Mattma/maFlgft/ft)
mouse strain, resulting in a lack of filaggrin protein in the skin.9We
recently separated the matted and filaggrin mutations present in
Mattma/maFlgft/ft flaky tail mice.10 We now show that filaggrin-
deficient mice, analogous to FLG mutations in human subjects,
have spontaneous dermatitis, become atopic and progress to lung
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gene implicated in the atopic march in human subjects, the roles
of innate versus adaptive immunity are shown in the initial
development of dermatitis and progression to aberrant lung
inflammation. Filaggrin-deficient mice on a BALB/c background
have a spontaneous expansion of IL-5–producing type 2 innate
lymphoid cells (ILC2s) into the skin, with an increase in skin
ILC2 numbers also seen in patients with FLGmutations, reinforc-
ing the role of innate immunity in the development of AD.
METHODS
Mice
Allmicewere congenicBALB/c strain,withBALB/cmice used aswild-type
(WT) control animals. TheFlgft andmamutations inflaky tail (Mattma/maFlgft/ft)
mice (Stock a/a ma ft/ma ft/JSun; JR#9078; Jackson Laboratories, Bar Harbor,
Me) were separated, and the Flgft mutation was backcrossed to the congenic
C57BL/6J background in accordance with previously published methods.10
Flgft/ftC57BL/6J congenicmicewere subsequently backcrossed to the congenic
BALB/c background, and these mice were used in this study. Il4KN2,11 Il5CFP,
Il13eGFP,12 Il17eGFP (Biocytogen, Worcester, Mass), and Rag1-deficient
(Jackson Laboratories) mice were crossed with Flgft/ft mice in house. Mice
expressing the luciferase transgene under the control of a nuclear factor kB
(NF-kB) promoter (NF-kB-Luc; Caliper Life Sciences, Hopkinton, Mass)
were crossed to Flgft/ft mice.
Mice were housed in specific pathogen-free conditions, with irradiated diet
and bedding and water ad libitum. All animal experiments were performed in
compliance with the Irish Department of Health and Children regulations and
approved by Trinity College Dublin’s BioResources ethical review board.
Clinical scoring
The severity of skin inflammation was clinically scored longitudinally by
using a system based on the macroscopic diagnostic criteria described by
Saunders et al10 and adapted from assessment of skin inflammation in the Nc/
Nga mouse model.13 In brief, a scoring system (0, none; 1, mild; 2, moderate;
and 3, severe) was applied to the signs of edema, erythema, scaling, and
erosion. The total score for each mouse was calculated from the sum of indi-
vidual scores for each parameter.
Analysis of airway hyperresponsiveness
Lung function or airway hyperresponsiveness (AHR) was analyzed in
32-week-old mice by using an invasive method in which mice were
tracheostomized and ventilated with whole-body plethysmography14 by usinga pneumotachograph linked to a transducer (EMMS,Hants, United Kingdom).
Changes in lung resistance (RL) and dynamic lung compliance (Cdyn) in
response to increasing doses of nebulized and inhaled methacholine (10, 30,
60, and 100 mg/mL; Sigma-Aldrich, St Louis, Mo) were recorded, as previ-
ously described.9,15Flow cytometric and cytokine analyses of human
suction blisters
Suction blistering was performed on patient donors after obtaining
informed written consent, and sample use was given ethical approval from
the NRES Committee South Central, United Kingdom. Patients with
moderate-to-severe AD were recruited and genotyped for FLG mutations
(see this article’s Online Repository at www.jacionline.org).5 Patients with
WT, heterozygous, and compound heterozygous FLG status were included
in the study. Suction blister cups were applied to the skin of patients with a
vacuum pressure of 200 to 400 mm Hg, as previously described.16 Blisters
were formed within 60 to 90 minutes, and suction was then removed.
Twenty-four hours later, fluid was aspirated with a 30-gauge needle. Fluids
were centrifuged at 1500 rpm for 5 minutes at 48C, and cell pellets were resus-
pended in RPMI 1640 supplemented with 10% human serum.
For surface staining, single-cell suspensions were prepared in flow
cytometry buffer. Live/dead violet (Invitrogen, Carlsbad, Calif) was used to
determine cell viability. Directly conjugated antibodies with fluorescein
isothiocyanate, phycoerythrin, phycoerythrin–Texas Red, peridinin-
chlorophyll-protein complex, peridinin-chlorophyll-protein complex–Cy5.5,
PeCy7, V450, allophycocyanin, and allophycocyanin-Cy7 were used. Human
cells were stained with the BioLegend (San Diego, Calif) mAbs CD4 (MEM-
241), CD8 (RPA-T8), CD11b (DCIS1/18), CD45 (H130), CD56 (B159),
FcεRI (AER-37 [CRA-1]), and IL-7 receptor a (IL-7Ra; A019D5); the BD
Biosciences (San Jose, Calif) mAbs CD3 (SK7), CD19 (SJ25C1), and CD14
(M4P9); the Abcam (Cambridge, United Kingdom) mAb CD11c (BU15); the
Miltenyi Biotec (Bergisch Gladbach, Germany) mAb chemoattractant
receptor–homologous molecule expressed on TH2 lymphocytes (BM16);
and the R&D Systems (Minneapolis, Minn) mAb CD123 (FAB301C). Cells
were acquired by using FACSDiva (BD Biosciences) or Summit software
(Beckman Coulter, High Wycombe, United Kingdom) on an LSRFortessa
or CyAn flow Cytometer, respectively. Lineage gating included CD3, CD4,
CD8, CD14, CD19, CD56, CD11c, CD11b, FcεRI, and CD123. ILC2s were
defined as Lin2CD451IL-7Ra1 chemoattractant receptor–homologous
molecule expressed on TH2 lymphocytes positive. FlowJo (TreeStar, Ashland,
Ore) and Summit softwarewere used for further data analysis. Blister fluidwas
analyzed with the MAGPIXMultiplex Array (Luminex, Austin, Tex), accord-
ing to the manufacturer’s instructions. Quantification of ILC2s and IL-1b
levels in patient samples was performed in a blinded manner.Statistical analyses
Data are expressed as means 6 SEMs and analyzed by using 2-way
ANOVA or the unpaired Student t tests (Prism 6; GraphPad Software, La Jolla,
Calif).RESULTS
Filaggrin deficiency leads to spontaneous
dermatitis and atopy
Single mutant Flgft congenic micewithout theMattmamutation
were generated (see Fig E1 in this article’s Online Repository at
www.jacionline.org) on the proallergic BALB/c background.17-19
Flgft/ft mice have attenuated profilaggrin expression in the
epidermis and absent functional filaggrin monomer (see Fig E2
in this article’s Online Repository at www.jacionline.org), which
is similar towhat is seen inFLG-null patients.5As neonates,Flgft/ft
mice spontaneously have marked ichthyosis-like dermatitis with
edema, erythema, hyperlinearity, and scaling compared with
FIG 1. Development of dermatitis and atopy in filaggrin-deficient mice. A, Macroscopic clinical scoring of
Flgft/ft versusWTmice. Data are from 25 to 30 mice per strain (scored longitudinally). Statistical significance
was determined with 2-way ANOVA. B, Gross phenotype of a representative Flgft/ft neonate in comparison
with a WT littermate. C, Gross phenotype of Flgft/ft and WT mice (age matched at 12 weeks). D, Represen-
tative image of the eczematous inflammation that develops in the eyelid skin of Flgft/ft mice at 12 weeks.
E, Representative hematoxylin and eosin–stained biopsy specimens of eyelid skin from 12-week-old Flgft/ft
and WT mice. Scale bar 5 200 mm. F and G, Epidermal acanthosis scoring (Fig 1, F) and dermal eosinophil,
neutrophil, and lymphocyte counts per high-power field (HPF; Fig 1,G) in lesional skin. Data are from 6 to 10
mice per strain. H, Total serum IgE levels from adult mutant and 12-week-old age-matched WT mice. I,
Transepidermal water loss (TEWL) at 12 weeks. Data are from 23 to 38 mice per strain. *P < .05,
**P < .01, and ****P < .0001.
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of skin inflammation shows that the early ichthyosis-like derma-
titis observed in neonatal Flgft/ft mice dissipates by 4 weeks,
with significant (P <.01) spontaneous eczematous-like dermatitis
developing in Flgft/ft mice from 8 weeks (Fig 1, A and C). By
12 weeks, all Flgft/ft mice have overt dermatitis, with eczematous
lesions occurring initially in eyelid skin (Fig 1, A and D). The
dermatitis, which is characterized by edema, erythema, scaling,
and lichenification (Fig 1, D), progresses with age to excoriation
and severe pathology,with pruritic erythematous lesions progress-
ing beyond the eyelid skin to around the eye and rostrum at
32 weeks (see Fig E3, A, in this article’s Online Repository at
www.jacionline.org).Histopathologic analysis of skin at 12weeks
demonstrates profound acanthosis (P < .0001) in Flgft/ft mice
(Fig 1, F), and significant infiltration of eosinophils (P < .0001),
neutrophils (P <.01), and lymphocytes (P <.0001) into the dermis
(Fig 1,G). By 32 weeks, an increasing incidence of erythema and
edema is evident in tail skin (see Fig E3,B) and the ear pinnae (seeFig E3, C), indicating a spectrum of pathology at these sites. Ear
histopathology in Flgft/ftmice (see Fig E3, C) shows significantly
increased acanthosis (see Fig E3, D) and inflammatory cell infil-
trates in the dermis (data not shown). Thus Flgft/ft mice on a
BALB/c background spontaneously have ichthyosis as neonates
and frank eczematous dermatitis in adulthood.Filaggrin-deficient mice are atopic with an altered
immunologic cutaneous environment
An increased IgE level is a cardinal marker of AD.20 Flgft/ft
mice had significantly (P < .0001) increased serum IgE levels at
12 weeks (Fig 1, H), indicating AD-like dermatitis. Addressing
skin barrier integrity, the significantly (P < .05) increased transe-
pidermal water loss21 demonstrated skin barrier dysregulation in
Flgft/ftmice (Fig 1, I). By using NF-kB reporter mice, NF-kB acti-
vation was observed in the skin of Flgft/ftNF-kB–Luc neonates
(see Fig E3, E), and the level of NF-kB activation was
FIG 2. Skin inflammation in filaggrin-deficient mice. A, Fold change in Ifng,
Il4, and Il17mRNA expression (n5 6-8 per group) in skin. Data are represen-
tative of 3 experiments. B-D, Cytokine quantification in nonlesional skin ex-
pressed as nanograms of cytokine per milligram of protein. Data are from
25 to 35 mice per strain. Statistical significance was determined with the
Student t test. *P < .05 and **P < .01. NS, Nonsignificant.
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Flgft/ftNF-kB–Luc mice (see Fig E3, F and G). Furthermore,
Flgft/ft mice have significantly increased contact hypersensitivity
skin inflammation (P <.01) in response to oxazolone hapten22 at a
dose evoking limited skin inflammation in WT mice (see Fig E4
in this article’s Online Repository at www.jacionline.org). There-
fore filaggrin deficiency leads to a defective skin barrier, with sub-
clinical cutaneous inflammation in nonlesional skin, and is
accompanied by a lower threshold for skin inflammation after
exposure to hapten.
Gene expression analysis of lesional eyelid skin in 12-week-old
Flgft/ft mice (Fig 2, A) demonstrated increased Ifng, Il4, and Il17
transcripts, which are typical of mixed type 1, 2, and 17 cutaneous
cytokine responses in lesional inflamed skin. Given the dysregu-
lated skin barrier and increased NF-kB activity in the uninvolved
skin of Flgft/ft mice, the basal inflammatory state of nonlesional
skin was addressed by quantifying cytokines in Flgft/ft and WT
skin (Fig 2,C-E, and see Fig E5 in this article’s Online Repository
at www.jacionline.org). In nonlesional Flgft/ft skin therewas a sig-
nificant (P <.01) approximately 50% upregulation in the levels of
IL-4, IL-17, and IFN-g (Fig 2,B) in addition to IL-1b (P <.01; Fig
2, C). Because the alarmin cytokines IL-25, IL-33, and thymic
stromal lymphopoietin (TSLP) are implicated in the pathogenesis
of allergic skin inflammation in experimental models and patients
with AD,16,23-26 we evaluated alarmin expression in Flgft/ft mice.
IL-25 was significantly (P < .05) upregulated in Flgft/ft skin,
whereas IL-33 and TSLP levels were not (Fig 2, D). There were
no differences between Flgft/ft and WT mice for other cytokines
assayed (see Fig E5). These data demonstrate that filaggrin-
deficient mice spontaneously become atopic, with dysregulated
skin barrier function. Flgft/ft mice have cutaneous subclinical
inflammation characterized by a generalized immune response
with increased cardinal TH1, TH2, and TH17 cytokine levels, as
well as selective upregulation of IL-1b and IL-25 in nonlesional
skin.Filaggrin-deficient mice have an expansion of type 2
innate lymphoid cells in the skin
Because IFN-g, IL-4, and IL-17 levels were increased in the
skin of Flgft/ft mice, we examined the cellular source of these cy-
tokines. IFN-g1CD41 TH1 cell frequency in the draining lymph
nodes (dLNs) was comparable between Flgft/ft and WT mice
(Fig 3, A). Generating dual Flgft/ft-IL-4–KN211 reporter mice
demonstrated a significantly (P < .01) increased frequency of
TH2 cells in Flg
ft/ft mice (Fig 3, A). The use of Flgft/ftIL-17–
enhanced green fluorescent protein (eGFP) reporter mice showed
increased frequency (P < .01) of both IL-17–eGFP1CD41
TH17 cells (Fig 3, A) and IL-17–eGFP
1 gd T cells (Fig 3, B) in
the dLNs of Flgft/ft mice.
The alterations in type 2 and type 17 responses led us to
examine the role of the recently described innate lymphoid cells,
which were classified as negative for lineage markers and
expressing IL-7Ra (CD127), CD25, and CD90, which have
been investigated in a number of inflammatory diseases.27-29
ILC2s are implicated in allergy; are regulated by IL-25, IL-33,
and TSLP; are characterized by expression of the transcription
factors GATA3 and retinoic acid–related orphan receptor (ROR)
a; and produce the type 2 cytokines IL-5, IL-9, and IL-
13.27,29,30 Recently ILC2 numbers have been shown to be
increased in the skin of patients with AD and also in mouseskin after chemical (MC903)– and allergen (house dust mite)–eli-
cited cutaneous inflammation.16,25 In the skin of WT mice,
numbers of resident ILC2s (Lin2ST21KLRG1loIL-7Ra1Thy-
1loSca-1hi; see Fig E6, A, in this article’s Online Repository at
www.jacionline.org) correspond to the natural type 2 innate
lymphoid cell (nILC2) classification that has recently been
defined as distinct from the IL-25–elicited inflammatory type 2
innate lymphoid cell (iILC2) population in the lung.31 In the
skin of Flgft/ft mice, there is a significant (P < .01) increase in
the frequency of nILC2s compared with the frequency in WTan-
imals (Fig 3, C and D). In addition, there is a KLRG1int ILC2 in
mouse skin (see Fig E6, A), which lacks ST2 expression consis-
tent with iILC2s31; however, iILC2s are KLRG1hi and are a
distinct population. There was no difference in the frequency of
KLRG1int ILC2s in Flgft/ft mice compared with WT mice (Fig
3, C and D). Consistent with the absence of the iILC2s in the
skin of Flgft/ft mice, we also do not see this population after
4 days of treatment of WT ear skin with MC903 (see Fig E7, A,
in this article’s Online Repository at www.jacionline.org). How-
ever, as reported,31 after 3 days of intraperitoneal treatment
with recombinant IL-25 but not IL-33, iILC2 numbers are
increased in the lungs of WT mice (see Fig E7, B). In contrast
to the lung, after 3 days of intradermal treatment in ear skin
with recombinant IL-25, there is a negligible influx of iILC2s
(see Fig E7, C), indicating that iILC2s might not be upregulated
in the skin on inflammation.
Previously, a study demonstrated, by using quantitative
RT-PCR, that activated skin ST21 ILC2s produced more IL-5,
leading to eosinophil influx and development of spontaneous
dermatitis.26 We have generated a novel IL-5–cerulean fluores-
cent protein (CFP) reporter mouse to accurately quantify IL-5–
expressing ILC2s in the skin (see Fig E8, A-C, in this article’s
FIG 3. Filaggrin deficiency leads to an increase in ILC2 numbers in the skin. A, Frequency of TH1 (CD4
1IFN-
g1), TH2 (CD4
1IL-41), and TH17 (CD4
1IL-171) cells as a percentage of total cells in skin dLNs. B, Frequency of
IL-171 gd T cells as a percentage of total cells in skin dLNs. C, Expression of ST2 and KLRG1 on CD451Lin2
cells in the skin; outlined areas indicate nILC2s (red) or KLRG1int ILC2s (blue). D, Frequency of nILC2s (ST21)
and KLRG1int ILC2s (ST22) of CD451 cells (gated on Lin2 cells) between Flgft/ft andWTmice. E, Frequency of
IL-51 nILC2s (ST21) and IL-51 KLRG1int ILC2s (ST22) of CD451 cells (gated on Lin2 cells) between Flgft/ft and
WT mice. F, Frequency of IL-131 nILC2s (ST21) and IL-131 KLRG1int ILC2 (ST22) of CD451 cells (gated on
Lin2 cells) between Flgft/ft andWTmice. Data are representative of 3 experiments (n5 6-10 mice per group).
Statistical significance was determined with the Student t test. **P < .01 and ****P < .0001. NS,
Nonsignificant.
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the skin produce IL-5 in the steady state (see Fig E6, B and C).
Strikingly, having generated Flgft/ftIL-5–CFP reporter mice, there
was a significant (P < .01) increase in the frequency of IL-5–pro-
ducing nILC2s inFlgft/ftmice compared with levels inWT control
animals (Fig 3, C and E). In addition, numbers of nILC2s (see Fig
E9, A, in this article’s Online Repository at www.jacionline.org)
and IL-5–producing nILC2s (see Fig E9, B) were also increased
in the skin dLNs of Flgft/ft relative to levels in WT mice. Because
ILC2s express IL-13,12 IL-13–eGFP reporter mice were used to
look at IL-13–expressing ILC2s in the skin. In the skin of WT
mice, both nILC2s and KLRG1int ILC2s constitutively express
IL-13 in the steady state, with KLRG1int ILC2s havingmarginally
higher IL-13 expression (see Fig E6, D). However, Flgft/ftIL-13–
eGFP reporter mice demonstrated no differences in the frequency
of IL-13–producing nILC2s and KLRG1int ILC2s between Flgft/ft
and WT mice (Fig 3, F). Using Flgft/ftIL-17–eGFP reporter mice,
we examined whether the marked increase in IL-17–producing
CD451 cells in the skin of Flgft/ft mice (see Fig E9, C) correlated
with an increase in IL-17 production by innate lymphoid cells.We
found no IL-17–producing population in Flgft/ftmice (see Fig E9,
D). No differences were observed in numbers of ILC3s (Lin2IL-
7Ra1ST22RORgT1) in the skin (see Fig E9, E). Similarly, there
were no differences in numbers of ILC1s (Lin2IL-7Ra1 T-box
transcription factor [T-bet]1; see Fig E9, F). Using Flgft/ftKN2
IL-4 reporter mice, we investigated whether increased numbers
of IL-4–producing CD451 cells in the skin of Flgft/ft mice (see
Fig E9,G) corresponded to increased numbers of IL-4–producing
ILC2s. No ILC2 population produced IL-4 in the skin of Flgft/ft
mice (see Fig E9,H). In addition to IL-5–producing nILC2 expan-
sion, there was significantly increased skin infiltration of
eosinophils (P < .05; non-B/non-T-cells [NBNT] cells
SiglecF1CD11b1), mast cells (P < .01; NBNT ckit1FcεR11cells), and basophils (P < .0001; NBNT FcεR11ckit2 cells) in
Flgft/ft mice (see Fig E9, I). Collectively, Flgft/ft mice on a
BALB/c background have a cutaneous expansion of IL-5–produc-
ing nILC2s, with amixed type 2 and type 17 inflammatory milieu.Filaggrin-deficient mice have spontaneous
pulmonary inflammation
FLG mutations in human subjects predispose to asthma devel-
opment after AD occurrence, exemplifying the atopic march.7,8
Therefore we analyzed AHR in Flgft/ft mice. Similar to studies
on flaky tail mice,9 16-week-old Flgft/ft mice had AHR compara-
ble with that seen in WT control animals, with no pulmonary
inflammation (data not shown) despite having dermatitis (Fig 1,
A). When analyzing 32-week-old Flgft/ft mice with marked
dermatitis, significantly altered Cdyn was observed (Fig 4, A).
Flgft/ft mice had no differences in RL apart from at the highest
methacholine concentration (Fig 4, B). Significant changes in dy-
namic lung compliance, but not resistance in Flgft/ft mice, sug-
gests that aberrant lung function is predominately caused by
peripheral alterations, such as lung parenchyma elasticity, with
lesser effects on central airway function.32 In agreement with
this altered lung function, there were significantly (P < .01)
more cells in bronchoalveolar lavage fluid of Flgft/ft mice (see
Fig E10, A, in this article’s Online Repository at www.
jacionline.org), with a significant (P <.001) increase in neutrophil
and eosinophil numbers (Fig 4, C).
The compromised lung function in Flgft/ft mice older than
24 weeks was reflected in significant lung pathology with mixed
peribronchial cellular infiltrates observed in hematoxylin and
eosin–stained sections (Fig 4, D). Flgft/ftmice did not have goblet
cell hyperplasia, peribronchial eosinophilia, or marked airway oc-
clusion (data not shown). Consistent with altered peripheral
FIG 4. Spontaneous lung inflammation in filaggrin-deficient mice. A and B, Measurement of AHR as as-
sessed by Cdyn (Fig 4, A) and RL (Fig 4, B) in response to increasing doses of methacholine. Data are repre-
sentative of 3 experiments (n 5 6-8 mice per group). Statistical significance was determined with 2-way
ANOVA. C, Differential cell counts from bronchoalveolar lavage fluid. Data are representative of 3 experi-
ments (n 5 6-8 mice per group). Statistical significance was determined with the Student t test. D and E,
Representative hematoxylin and eosin–stained (Fig 4, D) and Masson trichrome–stained (Fig 4, E) lung tis-
sue. Scale bars 5 200 mm. F, Cytokine quantification in the lung expressed as nanograms of cytokine per
milligram of protein. Data are from 16 to 20 mice per strain. Statistical significance was determined with
the Student t test. *P < .05, **P < .01, and ***P < .001. NS, Nonsignificant.
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deposition (Fig 4, E), with significantly increased (P < .05)
collagen levels in the lungs of Flgft/ftmice (see Fig E10, B). Quan-
tification of pulmonary eosinophil peroxidase and myeloperoxi-
dase enzymatic activity (see Fig E10, C and D) indicated
increased eosinophil and neutrophil activity in the lungs of
Flgft/ft mice, which is in agreement with the increased numbers
of eosinophils and neutrophils in bronchoalveolar lavage fluid
(Fig 4, C). With respect to increased eosinophil numbers in the
skin and lungs of deficient mice, we also noted inflammation in
the upper esophagus of Flgft/ft mice (see Fig E11, A, in this arti-
cle’s Online Repository at www.jacionline.org) with significant
(P < .05) eosinophil infiltration (see Fig E11, B). However,
Flgft/ft mice do not have the overt esophageal pathology reported
in food allergen–induced models of eosinophilic esophagitis.33
In the inflamed lungs of Flgft/ft mice, levels of the type 2 cy-
tokines IL-4, IL-5, and IL-13 were significantly (P < .05-.01)
increased (Fig 4, F). IL-17 levels were significantly (P < .05)
increased in lung homogenates (Fig 4, F), as were levels of
IL-3 (P < .05), IL-6 (P < .05), and IL-21 (P < .05). We also
observed an increase in IL-25 levels in the lungs of Flgft/ft
mice (Fig 4, F), whereas levels of the other epithelial cytokines
(ie, IL-33 and TSLP) were unchanged (see Fig E10, E). Levels
of other cytokines assayed were comparable in the lungs ofWT and Flgft/ft mice (see Fig E10, E). These data demonstrate
the development of marked pulmonary inflammation with age
in Flgft/ft mice on a BALB/c background secondary to derma-
titis development, with decreased lung compliance, increased
parenchymal collagen deposition, and eosinophil and neutro-
phil infiltration with mixed type 2 and type 17 pulmonary
inflammation.Cutaneous inflammation occurs in filaggrin-
deficient mice in the absence of adaptive immunity
To assess the relative role of innate versus adaptive immunity in
the context of spontaneous skin and lung inflammation caused by
filaggrin deficiency, we crossed Flgft/ft and Rag12/2mice, gener-
ating T cell– and B cell–deficient Rag12/2Flgft/ft mice. Neonatal
Rag12/2Flgft/ft mice retain the erythematous scaly skin pheno-
type typical of Flgft/ft mice. Adult Rag12/2Flgft/ft mice had
eczematous eyelid lesions similar to Flgft/ft mice (Fig 5, A),
with a significant clinical score (Fig 5, B). Histopathology reveals
that Rag12/2Flgft/ft mice have marked inflammation (Fig 5, A),
with significantly increased epidermal acanthosis, and infiltration
of eosinophils (P <.001) and neutrophils (P <.01) into the dermis
(see Fig E12, A, in this article’s Online Repository at www.
jacionline.org) relative to Rag12/2 mice.
FIG 5. Dermatitis develops in filaggrin-deficient mice independent of adaptive immunity. A, Representative
images of inflammation in eyelid skin and representative hematoxylin and eosin–stained eyelid skin. Scale
bars 5 200 mm. B, Clinical scoring of eyelids at 12 weeks. Data are from 20 to 25 mice per strain. Statistical
significance was determined with the Student t test. C, Cytokine quantification in nonlesional skin ex-
pressed as nanograms of cytokine per milligram of protein. Data are from 16 to 20mice per strain. Statistical
significance was determined with the Student t test. D, nILC2 numbers in the skin. Data are representative of
3 experiments (n 5 6-10 mice per group). Statistical significance was determined with the Student t test.
**P < .01 and ****P < .0001. NS, Nonsignificant.
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biopsy specimens of Rag12/2Flgft/ft mice. Consistent with the
cutaneous innate immune milieu observed in the skin of Flgft/ft
mice, both IL-1b and IL-25 levels were significantly (P <.01) up-
regulated in nonlesional skin of Rag12/2Flgft/ft mice relative to
those in Rag12/2 control skin (Fig 5, C). However, IL-4, IL-17,
and IFN-g levels were unchanged in the skin (Fig 5, C), as
were IL-33 and TSLP levels (see Fig E12, B). No increases
were observed in the levels of other cytokines assayed (see Fig
E12, B). Importantly, inflammation observed in Rag12/2Flgft/ft
mice is associated with a significant (P < .01) cutaneous nILC2
expansion relative to that seen in Rag12/2 mice (Fig 5, D).
Rag12/2Flgft/ftmice do not have lung inflammation, as measured
based on compliance and resistance (see Fig E13, A and B, in this
article’s Online Repository at www.jacionline.org) and other
parameters (data not shown), as observed in Flgft/ft mice.
Although pulmonary IL-1b levels were increased (P < .05) in
Rag12/2Flgft/ft mice, there were no differences in the levels of
other cytokines analyzed (see Fig E13, C).
Adult Rag12/2Flgft/ft mice had eczematous eyelid lesions
with significant clinical scoring (Fig 5, B) but no lung inflam-
mation (see Fig E13, A-C). Rag12/2Flgft/ft mice were reconsti-
tuted with B and T cells to address whether adaptive immunity
exacerbated skin or lung inflammation. B cell– and T cell–re-
constituted Rag12/2Flgft/ft mice have more severe dermatitis
relative to that seen in Rag12/2Flgft/ft mice (see Fig E14, A,
in this article’s Online Repository at www.jacionline.org),
with significantly increased clinical scores (see Fig E14, B).
Furthermore, reconstituted Rag12/2Flgft/ft mice had marked
atopy, which was significantly greater than that seen in
Rag12/2 mice receiving B and T cells (see Fig E14, C). In
addition to more marked skin inflammation, B cell– and
T cell–reconstituted Rag12/2Flgft/ft mice had compromised
lung function with a specific significant alteration in Cdyn, indi-
cating progression to secondary lung inflammation (see FigE14, D). B cell– and T cell–reconstituted Rag12/2Flgft/ft
mice had no differences in RL (see Fig E14, E). These data
demonstrate that the spontaneous development of dermatitis
caused by filaggrin deficiency is mediated by innate immunity
involving upregulation of IL-1b, IL-25, and nILC2s, with
adaptive immunity required for the development of severe
skin pathology and progression to lung inflammation.ILC2s are expanded in the skin of patients with FLG
mutations
It has been reported recently that ILC2s are present in the
skin of patients with AD.16,25 Given the spontaneous expan-
sion in ILC2 frequency in the skin of filaggrin-deficient mice
(Fig 3), we investigated whether ILC2 frequency was altered
in the skin of patients with mutations in FLG. We now show
that there are increased ILC2 numbers (P 5 .06) in skin blis-
ters taken from nonlesional skin of patients with FLG muta-
tions5 compared with the skin of FLG WT subjects (Fig 6,
A). Furthermore, similar to the increase in IL-1b levels in
the skin of filaggrin-deficient mice (Fig 2), IL-1b levels are
significantly upregulated within the blister fluid of acute le-
sional skin from patients with moderate-to-severe AD with
FLG mutations compared with levels seen in those without
FLG mutations (Fig 6, B).DISCUSSION
Filaggrin mutations have been identified as the major genetic
predisposer to AD development and in the context of the atopic
march, the subsequent progression to AD-associated asthma. We
now show that filaggrin-deficient mice, which have a mutation
analogous to the filaggrin mutations found in human subjects, are
atopic, have spontaneous AD-like inflammation, and progress to
pulmonary inflammation with age. Emerging evidence from
FIG 6. ILC2s are expanded in the skin of patients with FLG mutations. A,
Chemoattractant receptor–homologous molecule expressed on TH2 lym-
phocytes (CRTH2)1IL-7Ra1 ILC2s (gated on Lin2CD451 cells) are upre-
gulated in skin suction blisters of patients with FLG mutations in
comparison with those of patients without FLG mutations. B, IL-1b is
upregulated in the blister fluid of acute lesional skin from patients
with AD with FLG mutations compared with those without FLG muta-
tions. Statistical significance was determined with the Mann-Whitney
test. *P < .05.
J ALLERGY CLIN IMMUNOL
VOLUME 137, NUMBER 2
SAUNDERS ET AL 489genome-wide association studies and Immunochip and tran-
scriptome analyses34-39 has highlighted the complexity of genetic
predisposition in humanAD. The polygenetic nature of dermatitis
is also evident in mice, with marked differences between BALB/c
and C57BL/6J strains in the magnitude of skin inflammation and
the functional genes involved.16,25 Herein filaggrin-deficient mice
were generated on a BALB/c background, a strain predisposed to
type 2/type 17–associated inflammation.17-19,40-42 BALB/c Flgft/ft
mice have spontaneous AD-like skin inflammation and pulmo-
nary inflammation unlike the filaggrin mutant on the C57BL/6J
background10 and the Flg deletion knockout C57BL/6 mouse.43
These contrasting phenotypes in mice, highlighting the gene-
modifying effects of strain background, are indicative of the
complexity of how loss-of-functionFLGmutations in human sub-
jects can lead to AD.
Flgft/ft mice have neonatal ichthyosis, with eczematous AD
inflammation developing with 100% penetrance in Flgft/ft mice
by 12 weeks. Skin barrier dysregulation in the nonlesional skin
ofFlgft/ftmice, as evidenced by transepidermal water loss, reflects
the epidermal barrier dysfunction that has been shown in nonle-
sional skin in patients with AD.44,45 Furthermore, the increased
susceptibility of Flgft/ft mice to contact hypersensitivity inflam-
mation indicates that the dysregulated barrier can facilitate
allergenic sensitization. Eczematous inflammation in filaggrin-
deficient mice is characterized by increased type 1, type 2, and
type 17 cytokines, indicating a generalized inflammatoryresponse in lesional skin. Expansion of TH2 and TH17 cells in
skin dLNs and IL-17–eGFP1 gd T cells indicates that the mixed
inflammatory cutaneous milieu resembles the dual TH2 and TH17
T-cell response in patients with AD.46 Importantly, development
of spontaneous lesions in Rag12/2Flgft/ft mice demonstrates that
dermatitis can occur in the absence of adaptive immunity. Howev-
er, we demonstrate that adaptive immunity is required for pro-
gression to secondary lung inflammation. A recent study
demonstrated that Rag22/2Flgft/ftmice (homozygous forMattma)
did not have dermatitis in the dorsal flank.47 Differences in terms
of the development of skin inflammation between both studies
may be due to the presence of the matted mutation (Mattma),
which is still present in the Rag22/2/Flgft/ft mice in the study
by Leisten et al,47 confounding direct comparison with our find-
ings, where only the Flgft mutation is present in mice; animal
housing conditions might also be a factor. However, similar to
our findings, this letter reports an increase in the frequency of
Lin2CD32Thy11IL7R1 innate lymphoid cells in Rag22/2Flgft/
ft mice in comparison with that in Rag22/2 control animals.47
Increased NF-kB activity in nonlesional skin of Flgft/ftmice in-
dicates basal subclinical cutaneous inflammation. Indeed,
although relatively modest, the increased IL-4, IL-17, and IFN-
g protein levels in nonlesional skin demonstrated a generalized
subclinical inflammatory milieu in the skin. Nonlesional skin
was assessed to investigate inflammatory mechanisms in the
barrier-dysregulated skin of Flgft/ft mice, avoiding potential com-
plications of secondary inflammation associated with lesional
skin. These data correlate with recent transcriptomic studies
analyzing the uninvolved skin of patients with AD and filaggrin
mutations, which demonstrated upregulation of TH1- and TH2-
associated transcripts.39 Importantly, upregulation of IL-1b in
the nonlesional skin of both Flgft/ft and Rag12/2Flgft/ft mice is
consistent with our previous work in which epidermal IL-1b
levels were increased in Flgft/ft mice and also in patients with
AD with filaggrin mutations,48 indicating a key role for IL-1b
in the dysregulated cutaneous environment arising from filaggrin
deficiency. Interestingly, we now show that IL-1b levels are upre-
gulated in the blister fluid of acute lesional skin of patients with
AD with FLG mutations in comparison with those in patients
with AD with WT FLG.
IL-25 and IL-33 are overexpressed in skin of patients with
AD,16,49-51 with TSLP overexpression associated with skin
inflammation in mice.52 Flgft/ft and Rag12/2Flgft/ft mice have
an increase in IL-25 levels, but not IL-33 and TSLP levels, in
nonlesional skin. Recent studies have shown roles for IL-25,
IL-33, and TSLP in eliciting ILC2s during cutaneous inflamma-
tion in transgenic mice after IL-2 treatment in response to
chemical and allergen challenge and in the skin of patients
with AD.16,24-26 Previously, it has been demonstrated that
dermal ILC2s in the steady state constitutively produce IL-13,
but on activation, this population expanded and switched to a
proinflammatory phenotype characterized by increased Il5
mRNA expression, which promoted eosinophil infiltration and
spontaneous dermatitis.26 Importantly, we now show a specific
upregulation of these activated IL-5–producing ILC2s in the
skin of Flgft/ft mice using a novel IL-5–CFP reporter mouse.
These ILC2s, which also constitutively express IL-13, corre-
spond to the nILC2s described by Huang et al.31 After intraper-
itoneal recombinant IL-25 treatment, we also observe an
increase in the lungs of the KLRG1hi iILC2 population recently
described,31 but we do not observe this population in the skin of
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treatment.
Further work is needed to define the expansion of distinct ILC2
subpopulations in different organs. Strikingly, the ILC2 expan-
sion in filaggrin-deficient mice translates to patients, with ILC2
frequency increased in skin suction blisters of patients with FLG
mutations compared with that seen in those without FLG muta-
tions. Collectively, the increased frequency of ILC2s in the
skin of human subjects with FLG mutations is comparable with
the phenotype that develops spontaneously in filaggrin-
deficient mice. Importantly, nILC2 numbers are also specifically
increased in the skin of Rag12/2Flgft/ft mice, indicating the
importance of ILC2s in the pathogenesis of skin inflammation
arising from skin barrier dysregulation caused by filaggrin defi-
ciency. Indeed, Rag12/2 mice have dermatitis associated with
ILC2 activity after treatment with IL-2–JES6-1.26 In addition
to ILC2 expansion, we also observed an increase in the numbers
of eosinophils, mast cells, and basophils in the skin of Flgft/ft
mice, which is similar to the phenotype seen with IL-2–JES6-
1–induced inflammation.26
Carriers of filaggrin mutations have an increased risk of AD-
associated asthma.7,8 Filaggrin-deficient mice have a striking age-
dependent progression to pulmonary inflammation characterized
by compromised lung function and involving parenchymal alter-
ations in lung physiologic dynamics. Decreased compliance in
filaggrin-deficient mice was associated with increased collagen
deposition and eosinophil and neutrophil infiltration of the lungs
with mixed type 2 and type 17 inflammatory responses, reflecting
aspects of pulmonary pathology associated with multiple asthma
phenotypes.53
Importantly, Rag12/2Flgft/ft mice do not have lung pathology,
demonstrating that the adaptive immune response is required for
the progression from dermatitis to pulmonary inflammation.
In summary, filaggrin deficiency in mice leads to the develop-
ment of features of the atopic march that occur in patients with
AD with FLG mutations. This study highlights how skin inflam-
mation in the context of dysregulated skin barrier function de-
velops independently of the adaptive immune response,
whereas the subsequent progression to compromised lung func-
tion requires adaptive immunity.
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Key messages
d Filaggrin-deficient mice have spontaneous AD-like inflam-
mation and progress to compromised pulmonary function,
reflecting the atopic march in patients with AD.
d AD-like inflammation in the context of filaggrin deficiency
is associated with a cutaneous expansion in IL-5–produc-
ing ILC2 numbers in mice, and in patients with AD with
FLG mutations, there is an increase in ILC2 infiltration of
the skin.
d In the absence of adaptive immunity, filaggrin-deficient
mice experience spontaneous skin inflammation but do
not have lung pathology.REFERENCES
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